[Proceedings: Disorders in the cellular immunity].
D000961:Antilymphocyte Serum / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D002006:Brucellosis / Q000276:immunology; D006084:Graft Rejection; D006087:Graft vs Host Reaction; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D007918:Leprosy / Q000276:immunology; D009181:Mycoses / Q000276:immunology; D011878:Radiotherapy / Q000009:adverse effects; D013601:T-Lymphocytes / Q000276:immunology; D014376:Tuberculosis / Q000276:immunology
D000961:Antilymphocyte Serum; D000970:Antineoplastic Agents
Störungen der zellulären Immunabwehr